ACC

iCAD’s ProFound AI Suite Uncovers Hidden Heart Disease Risk According to New Data Presented at American College of Cardiology Meeting

Retrieved on: 
월요일, 4월 8, 2024
Prevalence, Cardiovascular disease, Sudden death, Radiology, Blood, Risk, Physician, ICAD, Patient, Ageing, Stroke, Research, Breast, Angiography, Death, Woman, American College, Breast cancer, Literature, Prognosis, Moyamoya disease, ACC, Medical imaging

The 15-site prospective study included 2D screening mammograms from women ages 20 to 100, with a median age of 56.

Key Points: 
  • The 15-site prospective study included 2D screening mammograms from women ages 20 to 100, with a median age of 56.
  • “The ProFound BAC AI algorithm may provide a critical surrogate biomarker for women at risk of heart disease or stroke,” said Dana Brown, president and CEO of iCAD.
  • The study also suggests the ProFound Heart Health AI algorithm can standardize BAC detection, potentially improving efficiency and reducing variability among observers.
  • Early cardiovascular disease detection is key, as among asymptomatic women, the first manifestation of underlying coronary heart disease is often acute myocardial infarction (MI) or sudden death.

Positive Results for Patients with Non-obstructive Hypertrophic Cardiomyopathy Treated with Ninerafaxstat in the Phase 2 IMPROVE-HCM Trial Presented During a Late-Breaking Clinical Trial Session at ACC.24

Retrieved on: 
월요일, 4월 8, 2024
Blood pressure, Exercise, MRCP, Patient, Heart rate, Heart, Journal, Aes, Medical Center, Quality of life, Efficacy, Heart failure, American College, HCM, Clinical trial, CPET, ACC, Pharmaceutical industry

BOSTON, April 08, 2024 (GLOBE NEWSWIRE) -- Imbria Pharmaceuticals, Inc., a clinical stage, cardiometabolic company developing novel therapies designed to improve patient symptoms and functional capacity by enhancing cellular energetics, today announced that results from the Phase 2 IMPROVE-HCM clinical trial, evaluating ninerafaxstat in patients with symptomatic nHCM, were presented in a late-breaking clinical trial session at the American College of Cardiology’s Annual Scientific Session & Expo (ACC.24) and published in the Journal of the American College of Cardiology (JACC).

Key Points: 
  • “We are pleased with the IMPROVE-HCM clinical trial results presented today at ACC and simultaneously published in JACC, confirming the importance of these results for patients living with nHCM,” said Anne Prener, M.D., Ph.D., president and chief executive officer of Imbria Pharmaceuticals.
  • “Based on these positive results, we plan to initiate the Phase 3 FORTITUDE-HCM clinical trial in patients with symptomatic nHCM later this year.
  • Most treatment emergent adverse events (AEs) were self-limiting and mild to moderate in severity occurring in 24 ninerafaxstat treated patients (70.6%) vs. 20 patients on placebo (60.6%).
  • improved) from 31.2 to 30.9 in the ninerafaxstat treated group and worsened from 32.7 to 34.3 in the placebo group.

Milestone® Pharmaceuticals Announces Etripamil Data Demonstrating Patients’ Ability to Self-Manage Recurring PSVT, Presented at The American College of Cardiology Annual Meeting

Retrieved on: 
월요일, 4월 8, 2024
FACC, American College, Atrial flutter, Patient, Journal, History, Doctor of Philosophy, MD, Ventricular fibrillation, ACC, Pharmaceutical industry

“The promising results of this real-world design study demonstrated patients’ ability to self-manage multiple episodes of PSVT with etripamil,” said David Bharucha, MD, PhD, FACC, Chief Medical Officer of Milestone Pharmaceuticals.

Key Points: 
  • “The promising results of this real-world design study demonstrated patients’ ability to self-manage multiple episodes of PSVT with etripamil,” said David Bharucha, MD, PhD, FACC, Chief Medical Officer of Milestone Pharmaceuticals.
  • CARDAMYST™, the conditionally approved brand name for etripamil nasal spray, if approved, will be the first rapid, reliable, and at-the-ready option in the acute treatment of PSVT.
  • NODE-303 (ClinicalTrials.gov ID NCT04072835 ) evaluated self-administered etripamil (70 mg, nasal spray) in an outpatient setting for up to multiple episodes of PSVT, without prior test dosing.
  • Both the presentation and publication will be available on the Milestone Pharmaceuticals corporate website at the conclusion of the ACC presentation.

Esperion Presents Important New Data from CLEAR Outcomes at ACC.24 Highlighting Value of NEXLETOL® (bempedoic acid) Tablets in Diverse Populations Including Women, Hispanics/Latinx and Patients with Obesity

Retrieved on: 
일요일, 4월 7, 2024
Uric acid, Urinary tract infection, Anaphylaxis, Myocardial infarction, Common, Bronchitis, Patient, Atherosclerosis, FAHA, Cleveland Clinic, Bempedoic acid, Ezetimibe, Therapy, Anemia, Pain, MACE, Sinusitis, ACC, FOMA, FNLA, FACC, Obesity, Cardiovascular disease, Esperion Therapeutics, Abdominal pain, Risk, Gout, Spasm, Woman, American College, Body mass index, ESPR, Back pain, Outcome, ATP, Safety, Fatigue, Arthralgia, ANN, Angioedema, Kidney, Journal, Constipation, University, Adverse event, Pregnancy, CLEAR, Rash, MPH, Rupture, FDA, Molina Healthcare, JACC, Hypersensitivity, Health, Circulatory system, Tablet, CVD, Incidence, Diarrhea, Fetus, Gallstone, Diet, Excipient, Upper respiratory tract infection, Dietary supplement

ANN ARBOR, Mich., April 07, 2024 (GLOBE NEWSWIRE) -- Esperion (Nasdaq: ESPR) today announced the presentation of results from three pre-specified subgroups from CLEAR Outcomes at the 2024 American College of Cardiology’s Annual Scientific Sessions (ACC.24): women, Hispanic/Latinx, and patients with obesity. These results align with the American College of Cardiology’s robust diversity, equity and inclusion programs to drive cultural change across the profession and ensure that the cardiovascular care team is as diverse as the patients they care for and that all patients are represented in cardiovascular research. The data also reinforce the mission of the ACC: transforming cardiovascular care for all.

Key Points: 
  • “Bempedoic acid is the only FDA approved non-statin LDL lowering therapy to demonstrate reductions in MACE in both primary prevention and secondary prevention patient populations.
  • The Hispanic population is the largest ethnic minority in the U.S., yet is a population historically underrepresented in clinical trials.
  • At Esperion, we discover, develop, and commercialize innovative medicines to help improve outcomes for patients with or at risk for cardiovascular and cardiometabolic diseases.
  • CLEAR Outcomes is part of the CLEAR clinical research program for NEXLETOL® (bempedoic acid) Tablet and NEXLIZET® (bempedoic acid and ezetimibe) Tablet.

EchoNous Announces Revolutionary AI Enhancements in Upcoming Kosmos Release for Apple iOS

Retrieved on: 
금요일, 4월 5, 2024
Cardiac output, SHM, ACP, POCUS, AIUM, Abdomen, IOS, TDI, Torso, Doppler effect, Workflow, Heart, Cosmos, ACC, IPhone, Medical imaging

REDMOND, Wash., April 05, 2024 (GLOBE NEWSWIRE) -- EchoNous, a leading innovator in ultrasound technology, is thrilled to announce the upcoming Kosmos 2.2 release on Apple iOS, a monumental update enriched with powerful new automated enhancements and significant workflow improvements, setting a new standard in point-of-care (POCUS) imaging.

Key Points: 
  • REDMOND, Wash., April 05, 2024 (GLOBE NEWSWIRE) -- EchoNous, a leading innovator in ultrasound technology, is thrilled to announce the upcoming Kosmos 2.2 release on Apple iOS, a monumental update enriched with powerful new automated enhancements and significant workflow improvements, setting a new standard in point-of-care (POCUS) imaging.
  • This feature is especially beneficial for new users, ensuring that they operate under the preset that will give them optimal image clarity.
  • These AI-driven features exemplify EchoNous’ commitment to enhancing user control while streamlining procedures, allowing for uninterrupted scanning and optimal imaging results.
  • EchoNous is excited to showcase these groundbreaking features at ACC and forthcoming shows such as AIUM, ACP, SHM, and ASE in the weeks ahead.

Cytokinetics Presents Additional 48-Week Data From FOREST-HCM, the Open Label Extension Clinical Study of Aficamten, at The American College of Cardiology 73ʳᵈ Annual Scientific Session

Retrieved on: 
금요일, 4월 5, 2024
Research, Week, Patient, SAN, Mercury (element), ACC, Cytokinetics, Hypertrophic cardiomyopathy

The updated data set presented at ACC in Atlanta focuses on 46 patients from FOREST-HCM that had completed 48 weeks of follow-up at the time of the current interim analysis.

Key Points: 
  • The updated data set presented at ACC in Atlanta focuses on 46 patients from FOREST-HCM that had completed 48 weeks of follow-up at the time of the current interim analysis.
  • At Week 48, 75% of these patients were receiving the 15 mg or 20 mg dose of aficamten.
  • Additionally, there were significant improvements in NT-proBNP, a biomarker of cardiac wall stress, with an average decrease of 63% from baseline to week 48 (p
  • There was a modest reduction in left ventricular ejection fraction (LVEF) from baseline to Week 48 (mean change from baseline (SD) = -5.1 mg (5.9), p

Cytokinetics Presents Additional 48-Week Data From FOREST-HCM, the Open Label Extension Clinical Study of Aficamten, at The American College of Cardiology 73ʳᵈ Annual Scientific Session

Retrieved on: 
금요일, 4월 5, 2024
Research, Week, Patient, SAN, Mercury (element), ACC, Cytokinetics, Hypertrophic cardiomyopathy

The updated data set presented at ACC in Atlanta focuses on 46 patients from FOREST-HCM that had completed 48 weeks of follow-up at the time of the current interim analysis.

Key Points: 
  • The updated data set presented at ACC in Atlanta focuses on 46 patients from FOREST-HCM that had completed 48 weeks of follow-up at the time of the current interim analysis.
  • At Week 48, 75% of these patients were receiving the 15 mg or 20 mg dose of aficamten.
  • Additionally, there were significant improvements in NT-proBNP, a biomarker of cardiac wall stress, with an average decrease of 63% from baseline to week 48 (p
  • There was a modest reduction in left ventricular ejection fraction (LVEF) from baseline to Week 48 (mean change from baseline (SD) = -5.1 mg (5.9), p

Applied Therapeutics to Present Results from Phase 3 ARISE-HF Study in Diabetic Cardiomyopathy at ACC 2024

Retrieved on: 
목요일, 4월 4, 2024
Diabetic cardiomyopathy, Patient, Journal, Diabetes, American College, Treatment, Therapy, Safety, ACC, JACC, Pharmaceutical industry

The presentation at ACC will also include important data on progression to overt heart failure and other secondary outcome measures.

Key Points: 
  • The presentation at ACC will also include important data on progression to overt heart failure and other secondary outcome measures.
  • AT-001 treatment prevented progression to overt heart failure in patients with DbCM as compared to placebo (p=0.0285).
  • The oral presentation at ACC will be followed by simultaneous publication of the study results in the Journal of the American College of Cardiology Journal (JACC).
  • A Selective Aldose Reductase Inhibitor (AT-001) For the Treatment of Diabetic Cardiomyopathy: Primary Results of the Phase 3 Randomized Controlled ARISE-HF Study
    Monday, April 8, 2024, 8:30 – 9:45 am ET, Main Tent (Hall B1)

RXO Expands Responsible Care® Certification

Retrieved on: 
월요일, 4월 8, 2024
Trucking, Manufacturing, Logistics, Supply Chain Management, Transport, Chemicals, Plastics, Health, Certification, Oil, American Chemistry Council, Safety, Responsible Care, EHS, ISO, Lubricant, ACC

RXO (NYSE: RXO), a leading provider of asset-light transportation, announced today it has expanded its Responsible Care® certification from the American Chemistry Council (ACC) to include brokerage operations at its Charlotte, North Carolina, headquarters.

Key Points: 
  • RXO (NYSE: RXO), a leading provider of asset-light transportation, announced today it has expanded its Responsible Care® certification from the American Chemistry Council (ACC) to include brokerage operations at its Charlotte, North Carolina, headquarters.
  • RXO has held a certification for more than 13 years.
  • Certification requires adherence to Responsible Care guiding principles, with assessments and audits ensuring compliance.
  • “RXO has held the Responsible Care certification for more than a decade in our managed transportation business, and we’re proud to expand this certification for our brokerage customers,” said Drew Wilkerson, chief executive officer at RXO.

LIB Therapeutics Announces Positive Results from LIBerate-HR Study: A 52-Week, Placebo-Controlled Registration-Enabling Trial of Lerodalcibep at Late-Breaking Session at American College of Cardiology 2024

Retrieved on: 
월요일, 4월 8, 2024
Science, Cardiology, Biotechnology, Research, Pharmaceutical, Health, Clinical Trials, Other Health, Week, Temperature, Cardiovascular disease, PCSK9, CVD, ADAS, FH, Patient, Travel, Female, Refrigeration, OLE, MBBS, Marketing, European Medicines Agency, American College, Therapy, Liberation, ITT, Safety, Food, ACC, Apolipoprotein B, Apolipoprotein, Pharmaceutical industry

Patients were randomized 2:1 to a single 300 mg (1.2 mL subcutaneous) once-monthly dose of Lerodalcibep or placebo for 52 weeks.

Key Points: 
  • Patients were randomized 2:1 to a single 300 mg (1.2 mL subcutaneous) once-monthly dose of Lerodalcibep or placebo for 52 weeks.
  • Of 478 participants in the base LIBerate-HeFH trial, 421 (88%) continued into the OLE trial: 281 patients on Lerodalcibep and 140 on placebo.
  • All participants received open-label Lerodalcibep 300 mg in a subcutaneous 1.2 mL once-monthly dose starting immediately upon completion of the base trial.
  • After 48 weeks of OLE treatment, mean % LDL-C reductions with Lerodalcibep from baseline in the base trial was 48.5% (ITT population).